Relapsing-remitting multiple sclerosis: Longitudinal analysis of MR images - Lack of correlation between changes in T2 lesion volume and clinical findings

Radiology

Volumn 213, Issue 2, 1999, Pages 395-399

  Miki, Yukio ^a,c   Grossman, Robert I ^a   Udupa, Jayaram K ^a   Wei, Luogang ^a   Polansky, Marcia ^b   Mannon, Lois J ^a   Kolson, Dennis L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Brain, diseases; Brain, MR; Magnetic resonance (MR), volume measurement; Sclerosis, multiple

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DISABILITY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NERVE LESION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE;

EID: 0032754839     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.213.2.r99oc01395     Document Type: Article

References (58)

1. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995; 118:1601-1612.
2. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis: US National MS Society Task Force. Ann Neurol 1996; 39:6-16.
3. Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25: 43-49.
4. Kiel MK, Greenspun B, Grossman RI. Magnetic resonance imaging and degree of disability in multiple sclerosis. Arch Phys Med Rehabil 1988; 69:11-13.
5. Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47:895-900.
6. Evans AC, Frank JA, Antel J, Miller DH. The role of MRI in clinical trials of multiple sclerosis: comparison of image processing techniques. Ann Neurol 1997; 41: 125-132.
7. Udupa JK, Wei L, Samarasekera S, Miki Y, van Buchem MA, Grossman RI. Multiple sclerosis lesion quantification using fuzzy connectedness principles. IEEE Trans Med Imaging 1997; 16:598-609.
8. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-231.
9. Udupa JK, Samarasekera S. Fuzzy connectedness and object definition: theory, algorithms and applications in image segmentation. Graphical Models and Image Processing 1996; 58:246-261.
10. Udupa JK, Wei L, Samarasekera S, Miki Y, van Buchem MA, Grossman RI. Detection and quantification of MS lesions using fuzzy topological principles. Proc SPIE 1996; 2710:81-91.
11. Miki Y, Grossman RI, Udupa JK, et al. Computer-assisted quantitation of enhancing lesions in multiple sclerosis: correlation with clinical classification. AJNR 1997; 18:705-710.
12. Samarasekera S, Udupa JK, Miki Y, Luogang W, Grossman RI. A new computer-assisted method for the quantification of enhancing lesions in multiple sclerosis. J Comput Assist Tomogr 1997; 21:145-151.
13. Miki Y, Grossman RI, Udupa JK, et al. Differences between relapsing-remitting and chronic progressive multiple sclerosis as determined with quantitative MR imaging. Radiology 1999; 210:769-774.
14. Miki Y, Grossman RI, Udupa JK, et al. Isolated U-fiber involvement in MS: preliminary observations. Neurology 1998; 50:1301-1306.
15. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452.
16. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308:173-180.
17. Koopmans RA, Li DK, Oger JJ, et al. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol 1989; 26: 248-256.
18. Koopmans RA, Li DK, Grochowski E, Cutler PJ, Paty DW. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol 1989; 25:74-81.
19. Kastrukoff LF, Oger JJ, Hashimoto SA, et al. Systemic lymphoblastoid Interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990; 40:479-486.
20. Baumhefner RW, Tourtellotte WW, Syndulko K, et al. Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging: its correlation with clinical parameters, evoked potentials, and intra-blood-brain barrier IgG synthesis. Arch Neurol 1990; 47:19-26.
21. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-661.
22. Paty DW, Li DKB. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial: the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667.
23. Paty DW, Li DK, Oger JJ, et al. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis. Ann Neurol 1994; 36(suppl):95-96.
24. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/ MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45:1277-1285.
25. Filippi M, Horsfield MA, Bressi S, et al. Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosis: a comparison of techniques. Brain 1995; 118:1593-1600.
26. Grimaud J, Lai M, Thorpe J, et al. Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn Reson Imaging 1996; 14:495-505.
27. Wicks DA, Tofts PS, Miller DH, et al. Volume measurement of multiple sclerosis lesions with magnetic resonance images: a preliminary study. Neuroradiology 1992; 34:475-479.
28. Filippi M, Barker GJ, Horsfield MA, et al. Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. J Neurol 1994; 241:246-251.
29. Filippi M, Horsfield MA, Campi A, Mammi S, Pereira C, Comi G. Resolution-dependent estimates of lesion volumes in magnetic resonance imaging studies of the brain in multiple sclerosis. Ann Neurol 1995; 38:749-754.
30. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995; 45:1808-1814.
31. Rovaris M, Gawne-Cain ML, Wang L, Miller DH. A comparison of conventional and fast spin-echo sequences for the measurement of lesion load in multiple sclerosis using a semi-automated contour technique. Neuroradiology 1997; 39:161-165.
32. Thorpe JW, Halpin SF, MacManus DG, Barker GJ, Kendall BE, Miller DH. A comparison between fast and conventional spin-echo in the detection of multiple sclerosis lesions. Neuroradiology 1994; 36: 388-392.
33. Miller DH. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 1994; 36(suppl):91-94.
34. Kappos L, Stadt D, Ratzka M, et al. Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis. Neuroradiology 1988; 30:299-302.
35. Pannizzo F, Stallmeyer MJ, Friedman J, et al. Quantitative MRI studies for assessment of multiple sclerosis. Magn Reson Med 1992; 24:90-99.
36. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44:635-641.
37. Johnston B, Atkins MS, Mackiewich B, Anderson M. Segmentation of multiple sclerosis lesions in intensity corrected multispectral MRI. IEEE Trans Med Imaging 1996; 15:154-169.
38. Broderick JP, Narayan S, Gaskill M, Dhawan AP, Khoury J. Volumetric measurement of multifocal brain lesions: implications for treatment trials of vascular dementia and multiple sclerosis. J Neuroimaging 1996; 6:36-43.
39. Bastianello S, Bozzao A, Paolillo A, et al. Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. AJNR 1997; 18:699-704.
40. Mitchell JR, Jones C, Karlik SJ, et al. MR multispectral analysis of multiple sclerosis lesions. JMRI 1997; 7:499-511.
41. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992; 42:60-63.
42. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 112:1057-1090.
43. Isaac C, Li DK, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988; 38:1511-1515.
44. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990; 113:1477-1489.
45. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HE Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29:548-555.
46. Noseworthy JH, Vandervoort MK, Wong C, Ebers GC. Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 1990; 1990:971-975.
47. Willoughby E, Paty D. Scales for rating impairment in multiple sclerosis: a critique. Neurology 1988; 38:1793-1798.
48. Goodkin D, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke expanded disability status scale (EDSS). Neurology 1992; 42:859-863.
49. Paty DW. Multiple sclerosis: assessment of disease progression and effects of treatment. Can J Neurol Sci 1987; 14:518-520.
50. Huber SJ, Paulson GW, Shuttleworth EC, et al. Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch Neurol 1987; 44:732-736.
51. Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989; 39:161-166.
52. Anzola GP, Bevilacqua L, Cappa SF, et al. Neuropsychological assessment in patients with relapsing-remitting multiple sclerosis and mild functional impairment: correlation with magnetic resonance imaging. J Neurol Neurosurg Psychiatry 1990; 53:142-145.
53. Swirsky ST, Mitchell DR, Seward J, et al. Neuropsychological and structural brain lesions in multiple sclerosis: a regional analysis. Neurology 1992; 42:1291-1295.
54. Grossman M, Armstrong C, Onishi K, et al. Patterns of cognitive impairment in relapsing-remitting and chronic progressive multiple sclerosis. Neuropsychiatry, Neuropsychol Behav Neurol 1994; 7:194-210.
55. Dousset V, Grossman RI, Ramer KN, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 1992; 182:483-491. [Erratum: Radiology 1992; 183:878.]
56. Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995; 45:478-482.
57. Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994; 36:157-165.
58. Sharrack B, Hughes RA. Clinical scales for multiple sclerosis. J Neurol Sci 1996; 135: 1-9.